Agenda for Day 1 - Monday December 7, 2026 - US/Pacific
- Barrett Land - Vice President of Market Access - Pricing & Contracting & Reimbursement, Jazz
- Samantha Elizondo - Conference Producer, Informa Connect
Government pricing teams are navigating a rapidly evolving policy environment shaped by IRA implementation, MFN developments, 340B reform efforts, PBM scrutiny, and increasing state-level activity. Rather than reviewing policy headlines, this discussion will focus on what these developments mean for pricing, rebates, contracting, and compliance teams responsible for execution.
Discussion Topics
Key policy developments expected to shape 2027 planning priorities
Where manufacturers are preparing for operational disruption
The growing gap between policy design and implementation realities
How organizations are prioritizing resources amid overlapping regulatory demands
Emerging areas of uncertainty that leaders should be monitoring now
- Rujul Desai - Senior Counselor to the Administrator, Centers for Medicare & Medicaid Services
Manufacturers are simultaneously preparing for MFN implementation, MFP negotiations, evolving rebate obligations, and increased reporting complexity. Hear how organizations are adapting systems, processes, and governance structures to manage growing operational demands.
Discussion Topics
Lessons learned from early MFN and MFP preparation efforts
System and data challenges created by overlapping regulations
Resource allocation and organizational readiness strategies
Balancing compliance requirements with business priorities
Preparing leadership teams for long-term operational impacts
- Barrett Land - Vice President of Market Access - Pricing & Contracting & Reimbursement, Jazz
- Dan Stefureak - Senior Director, Pricing & Contracting, Corecept Therapeutics
As manufacturers face increasing pressure from IRA implementation, 340B expansion, PBM reform efforts, and ongoing litigation, understanding the broader policy landscape has never been more critical. This session will provide an industry-wide view of the legal and regulatory developments most likely to impact pricing, contracting, and reimbursement strategies over the next 12–18 months.
Discussion Topics
Key IRA implementation and litigation updates
The future of 340B reform and duplicate discount policy
Government efforts to increase PBM oversight and transparency
Emerging manufacturer risks and compliance considerations
Legislative priorities shaping the industry’s policy agenda
- Jim Stansel - Executive Vice President and General Counsel, PhRMA
340B has become one of the most significant challenges facing manufacturers, yet many organizations continue to struggle with understanding the operational, commercial, and compliance implications. This discussion will explore how manufacturers are approaching duplicate discounts, revenue leakage, and evolving program requirements.
Discussion Topics
Revenue leakage and financial implications
Commercial contracting considerations
Alternative approaches
Rebate model pilot programs
Lessons learned from implementation efforts
- Joni Kane - Director, Commercial Contracting and Market Access Operations, Gilead Sciences
Commercial contracting decisions increasingly impact government pricing outcomes, while government pricing requirements are shaping commercial strategy. This discussion will explore how leading organizations are creating stronger alignment across pricing, contracting, finance, legal, and market access functions.
Discussion Topics
Understanding AMP, Best Price, and GTN relationships
Formulary strategy and rebate implications
Avoiding compliance risks created by siloed decision-making
Governance structures that support cross-functional alignment
Communicating pricing implications to executive leadership
- Jennesse Broom - Director - Government Programs & Pricing & Managed Markets Strategy & Operations, Gilead
- Jean Patel - Director of Government Pricing, Sumitomo Pharma America
- Elda Freitas - Associate Director, Government Pricing Reporting, Sumitomo Pharma America
- Jennifer Gunn - Senior Director Pricing & Contracting, Mineralys Therapeutics
State pricing transparency requirements continue to evolve, creating new reporting obligations, enforcement risks, and operational burdens for manufacturers. This session will focus on how organizations are navigating increasingly complex state requirements while balancing federal obligations and protecting proprietary information.
Discussion Topics
State enforcement trends and penalty exposure
Operationalizing compliance across multiple jurisdictions
Protecting confidential and trade-secret information
State versus federal reporting conflicts
Building scalable transparency compliance programs
- Gregg Kasten - Vice President, Technology and Services, ClassOne
Examine recent CMS guidance reshaping ASP calculation requirements and industry compliance expectations
Analyze the most significant bona fide service fee developments impacting manufacturers over the past two years
Review real-world case studies demonstrating successful and problematic BFSF structures under current standards
Explore documentation and cross-functional coordination requirements for ASP compliance
Discuss emerging regulatory trends and proactive risk mitigation strategies for ASP calculations
- Nick Ianconi - Associate Director, Government Pricing, Avyxa
Closed-door discussion groups for Director-level and above attendees.
Roundtable Topics
340B Reform & Duplicate Discounts
MFN & MFP Readiness
Medicaid Disputes & State Variability
Government Pricing Leadership Challenges
Commercial-Government Alignment
AI and Pricing & Contracting
- Jay Sinha - Pricing & Reimbursement Manager, Amgen
